What's happened
Kara Swisher's new series examines how health and tech aim to extend human lifespan, exploring treatments, industry hype, and scientific advances. Inspired by her father's death, she investigates everything from wellness influencers to AI-powered medical innovations, highlighting both promise and skepticism in longevity science.
What's behind the headline?
The series reveals a complex landscape where scientific progress and commercial interests collide. Swisher's neutral stance underscores the industry's hype, with many treatments lacking rigorous evidence. She highlights promising innovations like gene editing and AI diagnostics, but also criticizes the proliferation of unproven therapies exploiting consumer gullibility. The lack of regulation in longevity medicine raises concerns about safety and efficacy, emphasizing the need for scrutiny and scientific validation. Her exploration of AI and biotech demonstrates that while some advances could revolutionize healthcare, others remain speculative or driven by profit motives. This story forecasts a future where scientific breakthroughs will be tempered by regulatory oversight, but also warns of ongoing risks from unverified treatments that could harm consumers or undermine trust in legitimate science.
What the papers say
The Independent provides a detailed overview of Swisher's personal motivation and her investigative approach, emphasizing her balanced perspective and curiosity about scientific progress. AP News echoes her personal connection and her exploration of industry claims, highlighting her skepticism towards unproven therapies. The New York Times offers a critical view on the regulatory gaps in longevity medicine, pointing out that many practitioners operate without certification or oversight, which could lead to consumer harm. The contrasting tones—The Independent's curiosity-driven narrative, AP's personal touch, and the NYT's regulatory critique—illustrate the multifaceted nature of the longevity debate, from scientific promise to industry pitfalls.
How we got here
Swisher's interest in longevity stems from her father's death in 1968, which profoundly shaped her view of mortality. Her career covering Silicon Valley since the 1990s has positioned her to explore how technology intersects with health, especially as new scientific advances and industry claims emerge in the quest to prolong life.
Go deeper
More on these topics
-
Steven Paul Jobs was an American business magnate, industrial designer, investor, and media proprietor. He was the chairman, chief executive officer, and co-founder of Apple Inc., the chairman and majority shareholder of Pixar, a member of The Walt Disney
-
Jennifer Anne Doudna is an American biochemist known for her pioneering work in CRISPR gene editing and Nobel Laureate in Chemistry.
-
Samuel H. Altman is an American entrepreneur, investor, programmer, and blogger. He is the CEO of OpenAI and the former president of Y Combinator.
-
Bryan Johnson is an American entrepreneur, venture capitalist, writer and author. He is the founder and CEO of Kernel, a company that can monitor and record brain activity, and OS Fund, a venture capital firm that invests in early-stage science and techno
-
Kara Anne Swisher is an American technology business journalist and co-founder of Recode. She became a contributing writer to The New York Times Opinion Section in 2018.
-
Gwyneth Kate Paltrow is an American actress, businesswoman and author. She has received numerous accolades for her work, including an Academy Award, a Golden Globe Award, and a Primetime Emmy Award.